Beijing StarMab BioMed Technology Ltd. (StarMab) has entered a research evaluation agreement with Lonza, a global development and manufacturing partner to biopharma. The agreement gives StarMab access to Lonza’s XS® Pichia Expression System Toolbox to develop their proprietary multifunctional VHH antibodies.
You may also be interested in:
Read this article
Latest content
Latest briefing from the Knowledge Center